NASDAQ:VSTM Verastem - VSTM Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.42 -0.03 (-5.56%) (As of 03/22/2023 12:00 PM ET) Add Compare Share Share Today's Range$0.43▼$0.4550-Day Range$0.39▼$0.7152-Week Range$0.29▼$2.13Volume187,556 shsAverage Volume798,646 shsMarket Capitalization$85.29 millionP/E RatioN/ADividend YieldN/APrice Target$4.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Verastem MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside887.7% Upside$4.25 Price TargetShort InterestHealthy0.58% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.31Based on 8 Articles This WeekInsider TradingSelling Shares$8,900 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.01 out of 5 starsMedical Sector600th out of 983 stocksPharmaceutical Preparations Industry291st out of 478 stocks 3.5 Analyst's Opinion Consensus RatingVerastem has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.25, Verastem has a forecasted upside of 887.7% from its current price of $0.43.Amount of Analyst CoverageVerastem has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.58% of the outstanding shares of Verastem have been sold short.Short Interest Ratio / Days to CoverVerastem has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Verastem has recently increased by 5.45%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVerastem does not currently pay a dividend.Dividend GrowthVerastem does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VSTM. Previous Next 2.0 News and Social Media Coverage News SentimentVerastem has a news sentiment score of -0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Verastem this week, compared to 1 article on an average week.Search Interest14 people have searched for VSTM on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat Follows9 people have added Verastem to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verastem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,900.00 in company stock.Percentage Held by InsidersOnly 3.20% of the stock of Verastem is held by insiders.Percentage Held by Institutions60.59% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Verastem is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verastem is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerastem has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Verastem (NASDAQ:VSTM) StockVerastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.Read More Receive VSTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter. Email Address VSTM Stock News HeadlinesMarch 20, 2023 | americanbankingnews.comVerastem (NASDAQ:VSTM) Coverage Initiated at StockNews.comMarch 18, 2023 | americanbankingnews.comVerastem (NASDAQ:VSTM) Earns "Outperform" Rating from Royal Bank of CanadaMarch 22, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.March 15, 2023 | americanbankingnews.comVerastem (NASDAQ:VSTM) Stock Rating Reaffirmed by HC WainwrightMarch 15, 2023 | businesswire.comNew Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian CancerMarch 14, 2023 | finance.yahoo.comVerastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company ProgressMarch 12, 2023 | americanbankingnews.comVerastem (NASDAQ:VSTM) Now Covered by StockNews.comFebruary 2, 2023 | finance.yahoo.comVerastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven CancersMarch 22, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.January 30, 2023 | finance.yahoo.comVerastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock?January 24, 2023 | finance.yahoo.comVerastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian CancerJanuary 24, 2023 | finance.yahoo.comVerastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred StockJanuary 11, 2023 | finance.yahoo.comindividual investors who own 37% along with institutions invested in Verastem, Inc. (NASDAQ:VSTM) saw increase in their holdings value last weekJanuary 5, 2023 | seekingalpha.comVerastem: Avutometinib Apprehension Puts My Position In Mothballs (Rating Downgrade)December 20, 2022 | finance.yahoo.comVerastem, Inc. (VSTM) Stock Historical Prices & Data - Yahoo FinanceDecember 15, 2022 | finance.yahoo.comVerastem Oncology Appoints Rob Gagnon to Board of DirectorsNovember 8, 2022 | finance.yahoo.comVerastem Third Quarter 2022 Earnings: US$0.092 loss per share (vs US$0.13 loss in 3Q 2021)November 4, 2022 | finance.yahoo.comVerastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company ProgressOctober 20, 2022 | finance.yahoo.comVerastem Oncology Appoints Anil Kapur to Board of DirectorsOctober 4, 2022 | benzinga.comVerastem shares are trading lower after the company announced RAMP VS-6766 clinical trials and corporate updates. - Verastem (NASDAQ:VSTM) - BenzingaOctober 4, 2022 | businesswire.comVerastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates - Business WireOctober 4, 2022 | finance.yahoo.comVerastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate UpdatesSeptember 30, 2022 | nasdaq.comHealth Care Sector Update for 09/30/2022: ILMN, VSTM, TEVA - NasdaqSeptember 30, 2022 | nasdaq.comHealth Care Sector Update for 09/30/2022: OPGN,ILMN,VSTM,TEVA - NasdaqSeptember 26, 2022 | nasdaq.comVerastem, Inc.'s (NASDAQ:VSTM) 22% loss last week hit both individual investors who own 39% as well as institutionsSeptember 13, 2022 | seekingalpha.comVerastem: Moving Forward (NASDAQ:VSTM) - Seeking AlphaSeptember 5, 2022 | reuters.comVSTM.OQ - Verastem Inc | Stock Price & Latest News | ReutersSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VSTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter. Email Address VSTM Company Calendar Last Earnings11/04/2021Today3/22/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:VSTM CUSIP92337C10 CIK1526119 Webwww.verastem.com Phone(781) 292-4200FaxN/AEmployees48Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.25 High Stock Price Forecast$6.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+823.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-73,810,000.00 Net MarginsN/A Pretax Margin-2,843.30% Return on Equity-124.62% Return on Assets-69.85% Debt Debt-to-Equity Ratio0.52 Current Ratio4.29 Quick Ratio4.29 Sales & Book Value Annual Sales$2.60 million Price / Sales35.50 Cash FlowN/A Price / Cash FlowN/A Book Value$0.23 per share Price / Book2.00Miscellaneous Outstanding Shares200,680,000Free Float194,256,000Market Cap$92.31 million OptionableOptionable Beta0.81 Key ExecutivesBrian M. StuglikChief Executive Officer & DirectorDan PatersonPresident & Chief Operating OfficerDaniel CalkinsVP, Chief Financial & Accounting OfficerJonathan PachterChief Scientific OfficerLouis J. DenisChief Medical OfficerKey CompetitorsFortress BiotechNASDAQ:FBIOBolt BiotherapeuticsNASDAQ:BOLTSpectrum PharmaceuticalsNASDAQ:SPPIMerrimack PharmaceuticalsNASDAQ:MACKXOMANASDAQ:XOMAView All CompetitorsInsiders & InstitutionsBrian M StuglikSold 3,508 sharesTotal: $1,508.44 ($0.43/share)Robert E GagnonSold 1,664 sharesTotal: $715.52 ($0.43/share)Dan PatersonSold 2,339 sharesTotal: $1,005.77 ($0.43/share)Brian M StuglikSold 6,276 sharesTotal: $2,510.40 ($0.40/share)Robert E GagnonSold 3,654 sharesTotal: $1,461.60 ($0.40/share)View All Insider TransactionsView All Institutional Transactions VSTM Stock - Frequently Asked Questions Should I buy or sell Verastem stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VSTM shares. View VSTM analyst ratings or view top-rated stocks. What is Verastem's stock price forecast for 2023? 5 Wall Street research analysts have issued 12 month price targets for Verastem's stock. Their VSTM share price forecasts range from $3.00 to $6.00. On average, they expect the company's stock price to reach $4.25 in the next twelve months. This suggests a possible upside of 844.4% from the stock's current price. View analysts price targets for VSTM or view top-rated stocks among Wall Street analysts. How have VSTM shares performed in 2023? Verastem's stock was trading at $0.4025 at the beginning of the year. Since then, VSTM shares have increased by 11.8% and is now trading at $0.45. View the best growth stocks for 2023 here. When is Verastem's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our VSTM earnings forecast. How were Verastem's earnings last quarter? Verastem, Inc. (NASDAQ:VSTM) announced its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.05. What is Robert Forrester's approval rating as Verastem's CEO? 11 employees have rated Verastem Chief Executive Officer Robert Forrester on Glassdoor.com. Robert Forrester has an approval rating of 100% among the company's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Verastem own? Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Amarin (AMRN) and Viking Therapeutics (VKTX). What is Verastem's stock symbol? Verastem trades on the NASDAQ under the ticker symbol "VSTM." Who are Verastem's major shareholders? Verastem's stock is owned by a variety of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.87%), Jefferies Financial Group Inc. (0.78%), Millennium Management LLC (0.51%), Renaissance Technologies LLC (0.29%), Two Sigma Investments LP (0.26%) and Dimensional Fund Advisors LP (0.25%). Insiders that own company stock include Brian M Stuglik, Dan Paterson, Daniel Calkins, Ra Capital Management, LP, Robert E Gagnon and Timothy J Barberich. View institutional ownership trends. How do I buy shares of Verastem? Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Verastem's stock price today? One share of VSTM stock can currently be purchased for approximately $0.45. How much money does Verastem make? Verastem (NASDAQ:VSTM) has a market capitalization of $90.31 million and generates $2.60 million in revenue each year. The biopharmaceutical company earns $-73,810,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. How can I contact Verastem? Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The official website for the company is www.verastem.com. The biopharmaceutical company can be reached via phone at (781) 292-4200 or via email at bsullivan@verastem.com. This page (NASDAQ:VSTM) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.